Dianthus Therapeutics (Nasdaq: DNTH) announced that on August 3, 2026, its independent Compensation Committee granted equity inducement awards to six newly hired non-executive employees under Nasdaq Listing Rule 5635(c)(4). The grants consist of non-qualified stock options to purchase an aggregate of 87,000 shares of common stock at an exercise price of $106.02 per share, with a 10-year term.
According to Dianthus, the options vest 25% on the first anniversary of the vesting commencement date and then in equal monthly installments over the following 36 months. The awards are issued under the company’s Equity Inducement Plan and individual stock option agreements.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
DNTH's active S-3 shelf, effective through January 28, 2029, adds financing context to these employe...
Analysis
DNTH's active S-3 shelf, effective through January 28, 2029, adds financing context to these employee awards. Recent insider data showed Net Selling, while future grant announcements and equity-related filings remain relevant to monitor.
Key Figures
Grant date:August 3, 2026New employees:6 employeesShares under option:87,000 shares+4 more
7 metrics
Grant dateAugust 3, 2026Inducement awards
New employees6 employeesNewly hired, non-executive employees
Shares under option87,000 sharesAggregate common stock subject to options
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
non-qualified stock optionsfinancial
"consist of non-qualified stock options to purchase an aggregate"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on August 3, 2026, to six newly-hired, non-executive employees.The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants consist of non-qualified stock options to purchase an aggregate of 87,000 shares of the Company's common stock with a 10-year term and an exercise price of $106.02 per share.The options vest as to 25% on the first anniversary of the vesting commencement date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan, and the terms and conditions of a stock option agreement.
About Dianthus Therapeutics Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
What inducement equity grants did Dianthus Therapeutics (NASDAQ: DNTH) announce on August 3, 2026?
Dianthus Therapeutics announced non-qualified stock option inducement grants to six newly hired non-executive employees. According to Dianthus, these options cover an aggregate of 87,000 shares of common stock and were approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
How many DNTH shares are covered by the new Dianthus Therapeutics inducement stock options?
The inducement stock options cover an aggregate of 87,000 shares of Dianthus common stock. According to Dianthus, these options were granted as material inducements to employment for six new non-executive employees and are issued under the company’s Equity Inducement Plan and option agreements.
What is the exercise price and term of the Dianthus Therapeutics (DNTH) inducement options granted in August 2026?
The inducement options have an exercise price of $106.02 per share and a 10-year term. According to Dianthus, these are non-qualified stock options granted on August 3, 2026, to six newly hired non-executive employees under Nasdaq Listing Rule 5635(c)(4).
How do the August 2026 Dianthus Therapeutics DNTH inducement grants vest for new employees?
The options vest 25% on the first anniversary of the vesting commencement date, then monthly over 36 months. According to Dianthus, this schedule provides four years of total vesting, subject to the Equity Inducement Plan and individual stock option agreements’ terms and conditions.
Why did Dianthus Therapeutics use Nasdaq Listing Rule 5635(c)(4) for these DNTH inducement grants?
Dianthus used Nasdaq Listing Rule 5635(c)(4) to make equity awards as material inducements to employment. According to Dianthus, the rule permits granting stock options to new employees without shareholder approval when awards are a material condition of accepting employment with the company.
